BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Biotherapeutics

Date

Tuesday 10, September 2019

Chairs

Thomas Huber (Novartis, Switzerland)
Stefan Weigand (Roche, Switzerland)
Renè Assenberg (Janssen Biologics, Netherlands)

Abstract:

Disruptive innovations are driving future biotherapeutics to become more personalized, cost-effective and efficacious. The biotherapeutics are shifting from classical monoclonal antibodies towards more complex modalities, such as engineered antibodies, multi-specific antibodies, cell and gene therapies. The 2019 biotherapeutics forum discusses technology trends and developments required to progress current and future drug modalities from concepts to the market.